Many digital health companies, afraid of the costs and timeline of a proper GDPR implementation, opt for a strategy to store personal and sensitive data inside the devices, hoping to circumvent the regulation.
After the invalidation of the previous adequacy decision on the EU-US Privacy Shield, the US is still considered TODAY a Third country without an Adequacy Decision according to GDPR.
Although the tool can boost AI innovation, it is crucial to keep in mind that there are still some “grey areas” on the data protection and privacy side. We will focus our assessment on the GDPR.
The EU is preparing the world’s first proposal for regulating AI. This new regulation will likely become a global gold standard and a blueprint for other nations outside the EU.
Privacy can limit the amount of available data in healthcare. Sometimes, It seems like it is not possible to benefit from the AI advantages while keeping intact and safe patients’ data.
It’s never too late to tackle GDPR and transform it into a unique opportunity to gain trust, build solid relationships with your customers and partners and grow better.
The EU project will conduct research dedicated to identifying and understanding these mechanisms and will simultaneously develop suitable treatment methods for patients based on the findings.